GLS 0.00 Gelesis Holdings, Inc.
| Range: | 0.012-5.67 | Vol Avg: | 570667 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.99 | Cap: | 0.01B | Currency: | USD | Exchange: | NYSE |
| Sector: | Healthcare | IPO: | Fri Jan 14 2022 | Empoloyees: | 93 | ||
| CUSIP: | 36850R204 | CIK: | 0001805087 | ISIN: | Country: | US | |
| CEO: | Mr. Yishai Zohar | Website: | https://www.gelesis.com | ||||
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow